Investigations of survivin

The past, present and future

Chun-Hei Cheung, Li Ting Cheng, Kwang Yu Chang, Huang Hui Chen, Jang-Yang Chang

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Survivin is a member of the inhibitors-ofapoptosis protein (IAPs) family. It promotes cell survival through interference with multiple cell cycle-related proteins such as INCENP and Aurora B kinase. Survivin also inhibits cell death through interference with both caspase-dependent and -independent cell apoptosis. Interestingly, recent evidence suggests that survivin may also play a role in the regulation of cancer cell autophagy. At the clinical level, studies on clinical specimens have shown that survivin expression is up-regulated in various human cancers and its up-regulation is associated with tumour resistance to both chemotherapy and radiation therapy. On the basis of these findings, survivin has been proposed as an attractive target for new anti-cancer interventions. However, despite the role that survivin plays in cancer cell survival and anti-drug response, the development of survivin inhibitors is relatively slow as compared to other therapeutic inhibitors for cancer treatment. In this review, the relationships between survivin expression and the causation of drug resistance in cancers are re-addressed. This review also summarizes the recent development of survivin inhibitors for clinical usage.

Original languageEnglish
Pages (from-to)952-961
Number of pages10
JournalFrontiers in Bioscience
Volume16
Issue number3
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Cells
Neoplasms
Aurora Kinase B
Oncology
Chemotherapy
Radiotherapy
Cell death
Caspases
Cell Survival
Pharmaceutical Preparations
Tumors
Proteins
Cell Cycle Proteins
Apoptosis
Autophagy
Drug Resistance
Causality
Cell Death
Up-Regulation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Cheung, Chun-Hei ; Cheng, Li Ting ; Chang, Kwang Yu ; Chen, Huang Hui ; Chang, Jang-Yang. / Investigations of survivin : The past, present and future. In: Frontiers in Bioscience. 2011 ; Vol. 16, No. 3. pp. 952-961.
@article{d63263ff97034d28bdcda16ea1dc106b,
title = "Investigations of survivin: The past, present and future",
abstract = "Survivin is a member of the inhibitors-ofapoptosis protein (IAPs) family. It promotes cell survival through interference with multiple cell cycle-related proteins such as INCENP and Aurora B kinase. Survivin also inhibits cell death through interference with both caspase-dependent and -independent cell apoptosis. Interestingly, recent evidence suggests that survivin may also play a role in the regulation of cancer cell autophagy. At the clinical level, studies on clinical specimens have shown that survivin expression is up-regulated in various human cancers and its up-regulation is associated with tumour resistance to both chemotherapy and radiation therapy. On the basis of these findings, survivin has been proposed as an attractive target for new anti-cancer interventions. However, despite the role that survivin plays in cancer cell survival and anti-drug response, the development of survivin inhibitors is relatively slow as compared to other therapeutic inhibitors for cancer treatment. In this review, the relationships between survivin expression and the causation of drug resistance in cancers are re-addressed. This review also summarizes the recent development of survivin inhibitors for clinical usage.",
author = "Chun-Hei Cheung and Cheng, {Li Ting} and Chang, {Kwang Yu} and Chen, {Huang Hui} and Jang-Yang Chang",
year = "2011",
month = "1",
day = "1",
doi = "10.2741/3728",
language = "English",
volume = "16",
pages = "952--961",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "3",

}

Investigations of survivin : The past, present and future. / Cheung, Chun-Hei; Cheng, Li Ting; Chang, Kwang Yu; Chen, Huang Hui; Chang, Jang-Yang.

In: Frontiers in Bioscience, Vol. 16, No. 3, 01.01.2011, p. 952-961.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Investigations of survivin

T2 - The past, present and future

AU - Cheung, Chun-Hei

AU - Cheng, Li Ting

AU - Chang, Kwang Yu

AU - Chen, Huang Hui

AU - Chang, Jang-Yang

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Survivin is a member of the inhibitors-ofapoptosis protein (IAPs) family. It promotes cell survival through interference with multiple cell cycle-related proteins such as INCENP and Aurora B kinase. Survivin also inhibits cell death through interference with both caspase-dependent and -independent cell apoptosis. Interestingly, recent evidence suggests that survivin may also play a role in the regulation of cancer cell autophagy. At the clinical level, studies on clinical specimens have shown that survivin expression is up-regulated in various human cancers and its up-regulation is associated with tumour resistance to both chemotherapy and radiation therapy. On the basis of these findings, survivin has been proposed as an attractive target for new anti-cancer interventions. However, despite the role that survivin plays in cancer cell survival and anti-drug response, the development of survivin inhibitors is relatively slow as compared to other therapeutic inhibitors for cancer treatment. In this review, the relationships between survivin expression and the causation of drug resistance in cancers are re-addressed. This review also summarizes the recent development of survivin inhibitors for clinical usage.

AB - Survivin is a member of the inhibitors-ofapoptosis protein (IAPs) family. It promotes cell survival through interference with multiple cell cycle-related proteins such as INCENP and Aurora B kinase. Survivin also inhibits cell death through interference with both caspase-dependent and -independent cell apoptosis. Interestingly, recent evidence suggests that survivin may also play a role in the regulation of cancer cell autophagy. At the clinical level, studies on clinical specimens have shown that survivin expression is up-regulated in various human cancers and its up-regulation is associated with tumour resistance to both chemotherapy and radiation therapy. On the basis of these findings, survivin has been proposed as an attractive target for new anti-cancer interventions. However, despite the role that survivin plays in cancer cell survival and anti-drug response, the development of survivin inhibitors is relatively slow as compared to other therapeutic inhibitors for cancer treatment. In this review, the relationships between survivin expression and the causation of drug resistance in cancers are re-addressed. This review also summarizes the recent development of survivin inhibitors for clinical usage.

UR - http://www.scopus.com/inward/record.url?scp=79955025768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955025768&partnerID=8YFLogxK

U2 - 10.2741/3728

DO - 10.2741/3728

M3 - Article

VL - 16

SP - 952

EP - 961

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 3

ER -